EIKONIZO THERAPEUTICS, INC.
Beverly, MA · Founded 2017 · CIK 0001735756 · Biotech · Private
HDAC6-selective small molecule inhibitors to restore titin stiffness in dilated cardiomyopathy
eikonizo.com →- Grants
- $1.3M
- 3 awards
- Sector median: 1
- Raised
- $2.4M
- 2 Form D · May 2018
- 101 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 21
- 5 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,000,000 | |
| Private capital raised | Form D · SEC | $371,352 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting HDAC6 to Modulate Titin Stiffness for Dilated Cardiomyopathy Therapy | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Mechanistic Validation of Selective Brain-Penetrant HDAC6 Inhibitors as a Disease- Modifying Treatment for Tauopathies including Alzheimer's Disease | $509,672 | |
| Federal grant | Department of Health and Human Services · Phase I · Next-Generation CNS-Penetrant HDAC6 Inhibitors: Proof-of-Principle in Parkinson's Disease | $499,766 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2535 | Deverra Therapeutics | — | $2.5M |
| 2536 | ELIAS Animal Health, LLC | — | $2.4M |
| 2537 | BIOIO, LLC | — | — |
| 2538 | EIKONIZO THERAPEUTICS, INC. | — | $2.4M |
| 2539 | Topos Bio, Inc. | — | $9.0M |
| 2540 | Addition Therapeutics | — | $28M |
| 2541 | NBO Pharma Inc. | — | $7.6M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Kevin KinsellaDirector
- Janice KranzDirector · Executive Officer
- William ShawDirector · Executive Officer
- Stacie WeningerDirector
Patents
- HDAC6 Inhibitors And Uses Thereofapplication
- HDAC6 Inhibitors And Uses Thereofgranted
- Metalloenzyme Inhibitor Compoundsapplication
- Inhibiting Histone Deacetylase 6application
- Oxadiazole HDAC6 Inhibitors And Uses Thereofgranted
- Oxadiazole HDAC6 Inhibitors And Uses Thereofapplication
- HDAC6 Inhibitors And Uses Thereofgranted
- Inhibiting Histone Deacetylase 6 (HDAC6)application
- Metalloenzyme Inhibitor Compoundsgranted
- Oxadiazole HDAC6 Inhibitors And Uses Thereofapplication
- HDAC6 Inhibitors And Uses Thereofapplication
- Metalloenzyme Inhibitor Compoundsgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.